Stock Scorecard



Stock Summary for Omeros Corporation (OMER) - $8.47 as of 3/28/2025 8:37:43 PM EST

Total Score

6 out of 30

Safety Score

25 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OMER

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OMER

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OMER

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OMER

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OMER (25 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for OMER

Bitcoin Falls To $85K, Altcoins Drop Ahead Of Inflation Data; Trump's Tariffs May Raise $800B, But Risks Loom; Tesla Faces EV Incentive Cuts In UK After Canada - Top Headlines While The U.S. Slept 3/28/2025 2:39:00 PM
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Omeros ( NASDAQ:OMER ) 3/28/2025 11:39:00 AM
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Incyte ( NASDAQ:INCY ) , Affirm Holdings ( NASDAQ:AFRM ) 3/17/2025 12:58:00 PM
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Aspira Womens Health ( NASDAQ:AWH ) , Aclarion ( NASDAQ:ACON ) 3/17/2025 11:40:00 AM
Iovance Biotherapeutics Shares Fell Today: What's Going On? - Iovance Biotherapeutics ( NASDAQ:IOVA ) 2/10/2025 9:18:00 PM
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA ) 2/10/2025 12:00:00 PM
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Omeros ( NASDAQ:OMER ) , NCR Atleos ( NYSE:NATL ) 12/23/2024 3:36:00 PM
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Snow Lake Resources ( NASDAQ:LITM ) , Bio-Path Hldgs ( NASDAQ:BPTH ) 12/19/2024 7:25:00 PM
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Omeros ( NASDAQ:OMER ) 12/19/2024 5:28:00 PM
Gold Falls Sharply, Lamb Weston Shares Plunge - Snow Lake Resources ( NASDAQ:LITM ) , Bio-Path Hldgs ( NASDAQ:BPTH ) 12/19/2024 5:24:00 PM

Financial Details for OMER

Company Overview

Ticker OMER
Company Name Omeros Corporation
Country USA
Description Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 3/31/2025

Stock Price History

Last Day Price 8.47
Price 4 Years Ago 6.43
Last Day Price Updated 3/28/2025 8:37:43 PM EST
Last Day Volume 389,481
Average Daily Volume 520,489
52-Week High 13.60
52-Week Low 2.61
Last Price to 52 Week Low 224.52%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -2.55
Free Cash Flow Ratio 3.98
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 2.96
Total Cash Per Share 2.13
Book Value Per Share Most Recent Quarter -2.66
Price to Book Ratio 8.44
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 4.93
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 57,950,000
Market Capitalization 490,836,500
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 5.65%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -348.46%
Reported EPS 12 Trailing Months -3.29
Reported EPS Past Year -2.24
Reported EPS Prior Year -1.88
Net Income Twelve Trailing Months -134,525,000
Net Income Past Year -117,813,000
Net Income Prior Year 47,417,000
Quarterly Revenue Growth YOY 14.90%
5-Year Revenue Growth 45.77%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 123,200,000
Total Cash Past Year 171,800,000
Total Cash Prior Year 194,900,000
Net Cash Position Most Recent Quarter -41,739,000
Net Cash Position Past Year -41,355,000
Long Term Debt Past Year 213,155,000
Long Term Debt Prior Year 315,287,000
Total Debt Most Recent Quarter 164,939,000
Equity to Debt Ratio Past Year -0.13
Equity to Debt Ratio Most Recent Quarter -14.32
Total Stockholder Equity Past Year -24,983,000
Total Stockholder Equity Prior Year 85,684,000
Total Stockholder Equity Most Recent Quarter -154,172,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -154,905,000
Free Cash Flow Per Share Twelve Trailing Months -2.67
Free Cash Flow Past Year 74,300,000
Free Cash Flow Prior Year -86,596,000

Options

Put/Call Ratio 0.17
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.07
MACD Signal -0.02
20-Day Bollinger Lower Band 6.50
20-Day Bollinger Middle Band 9.28
20-Day Bollinger Upper Band 12.07
Beta 2.04
RSI 52.50
50-Day SMA 6.00
150-Day SMA 4.49
200-Day SMA 5.75

System

Modified 3/28/2025 3:56:09 AM EST